Elevated levels of MARCH5 are associated with improved survival rates in patients with hepatocellular carcinoma (HCC), as its interaction with HBx reduces the oncogenic potential of HBx [80]. This evidence concerns the gene MARCHF5 and hepatocellular carcinoma.